Crystalys Therapeutics
PrivateLast Round
Series B
Jul 22, 2026
Est. Valuation
$280M
Total Funding Raised
$358M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing dotinurad, a next-generation URAT1 inhibitor, as a second-line therapy for gout.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Crystalys Therapeutics Comparables
Compare Crystalys Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LG Chem | 78% | |
| Simcere Pharmaceutical Group | 76% | |
| ApicHope Pharmaceutical Group Co.,Ltd. | 75% |
Crystalys Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 22, 2026 | ||||
| Series A | Sep 30, 2025 |
Key People
Founding team and executive leadership
Crystalys Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series B |
| Conrad Prebys Foundation | Series A |
| Prebys Ventures | Series B |
| Wedbush Healthcare Partners | Series A |
| Perceptive Advisors | Series B, Series A |
| KB Investment | Series B, Series A |
| Lightstone Ventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 28, 2026
Grew 28% QoQ, from 18 to 23 employees.
- Aug 22, 2026
Monthly visitors increased 38% MoM.
Recent news
Latest coverage and updates
- hiresSep 23, 2026
Crystalys Therapeutics Inc. hired Tim Walbert as chair on Sep 23rd '26.
- receives_financingJul 27, 2026
Crystalys Therapeutics Inc. received financing of $130M in Series B on Jul 27th '26.
- invests_into_assetsJul 22, 2026
Crystalys Therapeutics Inc. invested into assets: U.S. and European rights to the treatment on Jul 1st '24.
Crystalys Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Crystalys Therapeutics's valuation, stock price, and market status.
Is Crystalys Therapeutics a public or private company?
Crystalys Therapeutics is a private company.
What is the current stock price of Crystalys Therapeutics?
Crystalys Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Crystalys Therapeutics worth (valuation)?
Valuation information for Crystalys Therapeutics is not publicly available.
Can I buy Crystalys Therapeutics stock?
Crystalys Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Crystalys Therapeutics's last funding round?
Crystalys Therapeutics's most recent funding round was Series A on September 30, 2025.
Who are the main investors in Crystalys Therapeutics?
Key investors in Crystalys Therapeutics include Novo Holdings, Catalys Pacific, SR One.
Will Crystalys Therapeutics IPO soon?
No public IPO plans have been announced for Crystalys Therapeutics.
How can I track Crystalys Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Crystalys Therapeutics's secondary market activity and sign up for updates.